Polaris Pharmaceuticals-KY Announces Commitments Made at Time of Stock Listing and Subsequent Implementation Status

1. Factual Date: 115/07/01

2. Company Name: Polaris Pharmaceuticals Group Co., Ltd.

3. Relationship with Company (Please enter '本公司' or 'Subsidiary'):本公司 (Our Company)

4. Cross-shareholding Ratio: Not applicable

5. Reason for Occurrence: According to the letter No. 1111700849 issued by Taiwan Stock Exchange Corporation on March 25, 111, the commitments made by our company at the time of initial stock listing are as follows:

(i) Disclose the following matters in the 'Special Matters' section of the public offering memorandum:

1. The company engages in the research and development and manufacturing of biopharmaceutical new drugs, including the main sources of technology and patent protection, development progress of each new drug, market competitiveness, potential risks, and mitigation measures.

2. Since 2019, the company has invested in Contract Development and Manufacturing Organization (CDMO) services, including its development plans, competitive advantages, expected customer sources, potential risks, and mitigation measures.

3. The company requires substantial capital for both new drug R&D and CDMO operations. Future funding needs and planning, potential operational cash flow risks, and mitigation measures must be disclosed.

(ii) Extend the period for submitting shares to the central depository to three years, with only one-third eligible for withdrawal after each full year from the start of listing and trading.

(iii) Delete Article 42.1 of the Articles of Incorporation regarding independent directors convening shareholders' meetings prior to listing.

6. Mitigation Measures:

As of 115/07/01, the company's implementation status is as follows:

(i) The relevant content has been appropriately disclosed in the public offering memorandum for 'Cash Capital Increase, Issuance of New Shares, Pre-listing Public Offering, and Initial Listing' published in May 111. Refer to the Public Information Observation Station for details.

(ii) The period for submitting shares to the central depository has been extended to three years, with only one-third eligible for withdrawal after each full year from the start of listing and trading.

(iii) The amendment to the Articles of Incorporation was resolved at the shareholders' meeting held on June 2, 111.

7. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly issued company or above, this major information also qualifies as a matter under Article 7, Paragraph 9 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholders' rights or securities prices):

New drug development involves long timelines, high expenditures, and no guarantee of success, which may expose investors to risks. Investors should exercise careful judgment and invest prudently.